On Friday, Shares of IAMGOLD Corp (USA)(NYSE:IAG), added 1.55% and closed at $3.28 in the last trading session. The last trading range of the stock ranges between $3.14 and $3.39. The company’s Market capitalization is $1.51 Billion with the total Outstanding Shares of 450.66 million. During the 52-week trading session the minimum price at which share price traded, registered at $1.15 and reached to max level of $5.87. Jeff Currie, head of commodities research at Goldman Sachs, attributes part of the 20 percent rally in gold this year to uncertainty over the coming U.S. election. “We have a lot of political risk in the market right now, so gold has a planned purpose,” said Currie, explaining that shareholders often gravitate toward hard assets in times of uncertainty. Recent developments in the sector: GOLDCORP INC. (GG), Bullfrog Gold Corp (BFGC), IAMGOLD Corporation (IAG), Kinross Gold Corporation (KGC) and YAMANA GOLD INC. (AUY).
Bullfrog Gold Corp (BFGC) is happy to declare that Kjeld Thygesen has joined the Company as an independent Director. Mr. Thygesen brings 46 years of international credentials in the mining research and finance sectors and joins Alan Lindsay, Chairman and David Beling, President and CEO as a member of Bullfrog’s Board. Mr. Lindsay and Mr. Beling have been involved with Mr. Thygesen on many business matters for more than 24 years and very much look forward to his able contributions on behalf of the Company.
Gilead Sciences, Inc.(NASDAQ:GILD), lost -1.27% and closed at $75.24 in the last trading session. The last trading range of the stock ranges between $74.92 and $76.48. The company’s Market capitalization is $98.03 Billion with the total Outstanding Shares of 1.32 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $74.92 and reached to max level of $111.11. Gilead Sciences, Inc. (GILD) recently declared it has reached a partnership with the World Health Organization (WHO) to provide $20 million in funding and drug donations over five years to expand access to diagnostic services and treatment for visceral leishmaniasis (VL). As part of this collaboration, Gilead will donate 380,000 vials of AmBisome® (amphotericin B liposome for injection) to meet the needs of WHO to treat VL in key endemic countries, counting Bangladesh, Ethiopia, India, Nepal, South Sudan and Sudan.
VL, also known as kala-azar, is the world’s second-deadliest parasitic infectious disease and affects up to 300,000 people annually in resource-limited countries.
“This new partnershipcomes at the right time as we gear up to support endemic countries in the Eastern Africa sub-region and South-East Asia to eliminate visceral leishmaniasis as a public health problem by or before 2020,” said Dr. Ren Minghui, WHO Assistant Director-General for HIV/AIDS, Malaria and Neglected Tropical Diseases. “During the past five years, AmBisome, donated by Gilead, allowed many countries in the Region highly endemic for VL to implement WHO’s recommended first line treatment, benefitting thousands of people.”
On the other hand share Denbury Resources Inc.(NYSE:DNR), dropped -8.02% and closed at $2.98 in the last trading session. The last trading range of the stock ranges between $2.97 and $3.27. The company’s Market capitalization is $1.09 Billion with the total Outstanding Shares of 398.33illion. During the 52-week trading session the minimum price at which share price traded, registered at $0.86 and reached to max level of $4.80. Denbury Resources Inc. (DNR) (“Denbury” or the “Company”) recently declared that as part of its ongoing succession planning process, the Board of Directors has promoted Chris Kendall to President of the Company. Mr. Kendall will assume this position from Denbury’s Chief Executive Officer, Phil Rykhoek. Mr. Kendall joined Denbury as Chief Operating Officer in September 2015, and will continue to serve in that role until a successor is named.
Phil Rykhoek, CEO of Denbury commented, “The board and I congratulate Chris on this well-deserved promotion in recognition of his noteworthycontribution to our improved operations, as evidenced by our lower costs and improved efficiencies. Chris is a pleasure to work with and I anticipate that his expanded responsibilities will further enhance our continuing efforts to increase the value of the Company for our shareholders and employees.”